NYSE: CATX - Perspective Therapeutics, Inc.

Rentabilität für sechs Monate: -80.26%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Perspective Therapeutics, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc.

weitere details
and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2005-11-10
ISIN US46489V1044
Industry Health Care Equipment & Supplies
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.perspectivetherapeutics.com
Цена ао 2.62
Preisänderung pro Tag: -1.15% (2.62)
Preisänderung pro Woche: -0.7663% (2.61)
Preisänderung pro Monat: -14.52% (3.03)
Preisänderung über 3 Monate: -25.57% (3.48)
Preisänderung über sechs Monate: -80.26% (13.12)
Preisänderung pro Jahr: +142.06% (1.07)
Preisänderung über 3 Jahre: +640% (0.35)
Preisänderung über 5 Jahre: +181.52% (0.92)
Preisänderung über 10 Jahre: 0% (2.59)
Preisänderung seit Jahresbeginn: -21.28% (3.29)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 133.02 1
P/BV 17.29 1
P/E 0 0
EV/EBITDA -62.27 0
Gesamt: 0.875

Effizienz

Name Bedeutung Grad
ROA, % -25.25 0
ROE, % -26.85 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.1163 10
Gesamt: 9.6

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -2.68 0
Rentabilität Ebitda, % 179.96 10
Rentabilität EPS, % 42.79 6
Gesamt: 7.2
Weitere Details

Institutionen Volumen Aktie, %
Vanguard Group Inc 13213750 2.25
Baker Brothers Advisors, LLC 7639703 1.3
Blackrock Inc. 4538389 0.77
Geode Capital Management, LLC 2516649 0.43
Ghost Tree Capital, LLC 1600000 0.27
Osterweis Capital Management, Inc. 1582100 0.27
HighTower Advisors, LLC 1332238 0.23
Perkins Capital Management, Inc. 700000 0.12
State Street Corporation 671524 0.11
Taylor & Morgan Wealth Management, LLC 625000 0.11

ETF Aktie, % Rentabilität für das Jahr, % Dividenden, %
iShares Russell 2000 Growth ETF 0.04295 38.04 0.6026
iShares Morningstar Small-Cap Growth ETF 0.02697 33.63 0.72598
iShares Morningstar Small-Cap Growth ETF 0.02697 587.89 0.72598
iShares Morningstar Small-Cap ETF 0.01351 30.1 1.60498
iShares Morningstar Small-Cap ETF 0.01351 391.25 1.60498
iShares Russell 3000 ETF 0.00132 24.83 1.43482



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Johan M. Spoor CEO & Director 855.78k 1972 (53 Jahr)
Mr. Jonathan R. Hunt CFO and Principal Financial & Accounting Officer 944.35k 1967 (58 Jahre)
Mr. Shane Cobb Executive Vice President of Operations N/A
Dr. Michael K. Schultz Ph.D. Chief Science Officer N/A
Mr. Andrew Bright Executive Vice President of Brachytherapy N/A
Dr. Markus Puhlmann M.B.A., M.D. Chief Medical Officer 633.14k 1966 (59 Jahre)
Mr. Amos Hedt BA, PGradDip Chief Business Strategy Officer N/A
Dr. Frances L. Johnson M.D. Chief Innovation Officer N/A
Mr. David Hauser Ph.D. Senior Vice President of Clinical Operations N/A
Steve Keefe Senior Vice President of Clinical Development

Adresse: United States, Richland. WA, 350 Hills Street - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.perspectivetherapeutics.com